Sign Up to like & get
recommendations!
1
Published in 2018 at "Expert Opinion on Therapeutic Patents"
DOI: 10.1080/13543776.2018.1427735
Abstract: ABSTRACT Introduction: Monoamine oxidase (MAO) inhibitors, after the initial ‘golden age’, are currently used as third-line antidepressants (selective MAO-A inhibitors) or clinically enrolled as co-adjuvants for neurodegenerative diseases (selective MAO-B inhibitors). However, the research within…
read more here.
Keywords:
inhibitors wider;
patent review;
applications patent;
mao ... See more keywords